• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Gigaxonin (GAN)

ACP19143

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP19143 Target NameGAN
Target SynonymsFLJ38059; GAN (gene name); GAN; GAN_HUMAN; GAN1 (gene name); Gigaxonin; Kelch-like protein 16; KLHL16FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range1-597
Protein LengthFull length proteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9H2C0
Background Information
  • Uniprot Id

    Q9H2C0

  • Target Species

    Human

  • Target Name

    GAN

  • Target Full Name

    Gigaxonin

  • Target Function

    Probable cytoskeletal component that directly or indirectly plays an important role in neurofilament architecture. May act as a substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Controls degradation of TBCB. Controls degradation of MAP1B and MAP1S, and is critical for neuronal maintenance and survival.

  • Target Involvement

    Giant axonal neuropathy 1, autosomal recessive (GAN1)

  • Target Subcellular Location

    Cytoplasm. Cytoplasm, cytoskeleton.

  • Target Tissue Specificity

    Expressed in brain, heart and muscle.

  • Target Synonyms

    FLJ38059; GAN (gene name); GAN; GAN_HUMAN; GAN1 (gene name); Gigaxonin; Kelch-like protein 16; KLHL16

Inquire Recombinant Human Gigaxonin (GAN) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification